A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme
Clinical trial NCT05053880 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05053880
- Sponsor
- Accendatech USA Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-22
- Primary completion
- 2024-10-25
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.